The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global orthopedic soft tissue repair market reached a value of US$ 3.26 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 4.57 Billion by 2027, exhibiting a CAGR of 5.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Orthopedic soft tissue repair refers to the process of replacing the injured or damaged tissues with healthy tissues. It comprises nerves, ligaments, blood vessels, muscles, tendons and synovial membranes. Orthopedic soft tissue injuries often occur during sports and physical activities but can also be caused by simple everyday tasks and continuous use of a particular body part. Sprains, strains, bursitis, contusions, and tendinitis are some of the common soft tissue injuries that can result in swelling, pain, bruising and loss of function. The repair of orthopedic soft tissues can be performed through open surgical processes or by complete minimally invasive procedures such as arthroscopy. These procedures increase mobility, muscle strength, tissue length, and range of movement with reduced pain and swelling, thereby enhancing the healing process.
The rising geriatric population across the globe, which is more susceptible to injuries as a result of weakened ligaments and changes in skeletal and neuromuscular systems, is primarily driving the market growth. Additionally, the growing participation of individuals in professional sports has significantly increased the risks of sports-related injuries, which, in turn, is facilitating the demand for orthopedic soft tissue repair procedures. Apart from this, the introduction of new therapies, such as platelet-rich plasma, that are effective in managing complex neuromuscular pain caused due to orthopedic ligament tears are providing an impetus to the market growth. In line with this, the introduction of new technologies, including bioprinting, biological meshes, and biofabrication, is further creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, innovations in new devices and therapies, and increasing healthcare per capita expenditure, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global orthopedic soft tissue repair market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on procedure, injury location and end user.
Breakup by Procedure:
Breakup by Injury Location:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Arthrex Inc., Becton Dickinson and Company, Boston Scientific Corporation, CONMED Corporation, Integra LifeSciences, Johnson & Johnson, LifeNet Health, MTF Biologics, Smith & Nephew plc, Stryker Corporation, Tissue Regenix Group plc and Zimmer Biomet.
|Base Year of the Analysis||2021|
|Segment Coverage||Procedure, Injury Location, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Arthrex Inc., Becton Dickinson and Company, Boston Scientific Corporation, CONMED Corporation, Integra LifeSciences, Johnson & Johnson, LifeNet Health, MTF Biologics, Smith & Nephew plc, Stryker Corporation, Tissue Regenix Group plc and Zimmer Biomet.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at